GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

Aging & Longevity, Alzheimer's Research Corey Hubbafd Aging & Longevity, Alzheimer's Research Corey Hubbafd

Beyond the Plaque Trap: How Spinal Cord Drugs, Immune Sleep Fixes, and Smart Injections Are Transforming Global Alzheimer’s Care in 2026

Discover the first-week November 2026 Alzheimer's research breakthroughs. Learn how repurposed spinal cord drugs repair DNA, immune cells restore sleep, 5-year CTAD trial data proves longevity, and smart home healthtech supports caregivers.

Read More

Unlocking the Brain: Why NeuroDiscovery Matters and Where to Learn More

Neurodiscovery, in its broadest sense, encompasses the multidisciplinary field dedicated to unraveling the mysteries of the nervous system. It’s a vibrant tapestry woven from threads of neuroscience, biology, chemistry, physics, psychology, computer science, and even engineering. This collaborative effort aims to decipher how the brain develops, functions, and changes throughout life,

Read More

A New Lens on Alzheimer's: How GE HealthCare's Vizamyl is Revolutionizing Diagnosis and Treatment Monitoring

Imagine peering into the intricate workings of the human brain, not just to see its structure, but to uncover the subtle whispers of a disease that gradually erodes memory, thought, and ultimately, identity. For decades, Alzheimer's disease has presented a formidable challenge, often diagnosed only after significant cognitive decline has set in, and the opportunity for early intervention has diminished. But a recent development, spearheaded by the U.S. Food and Drug Administration (FDA) and GE HealthCare

Read More

Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind

There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.

Read More
Clinical Operations, FDA Compliance, NIH Corey Hubbafd Clinical Operations, FDA Compliance, NIH Corey Hubbafd

The Alzheimer’s Revolution: Simple Blood Tests Spotting Risk Years Before Symptoms

For decades, Alzheimer’s disease has been a silent and elusive adversary. It crawls slowly through the brain, dismantling neural connections and building up toxic protein barriers long before the first lapse in memory occurs. Traditionally, confirming a diagnosis of Alzheimer’s has been a reactive process. Patients and their families had to wait for undeniable symptoms—confusion, forgetfulness, and changes in behavior—before seeking medical confirmation. By the time these symptoms manifest, significant and often irreversible brain damage has already occurred.

Read More

Optimizing FDA Diversity Action Plan Compliance and Alzheimer’s Clinical Trial Matching Through Agentic AI

Discover how Glassbury AI leverages agentic NLP, SMART on FHIR protocols, and trust-centric community frameworks to solve Alzheimer's trial enrollment bottlenecks, de-risk asset beta, and automate FDA Diversity Action Plan (DAP) compliance under FDORA.

Read More

Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research

Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.

Read More